|
Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa Clinical research trials and Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa. Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa clinical trial. Human subjects often receive the most effective healthcare possible for their Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa  Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa
Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa
For Condition: HIV Infections
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: The purpose of this study is to see if different doses of an experimental HIV vaccine are safe and to study how the immune system responds to the vaccine. The vaccine will be tested in healthy, HIV uninfected volunteers. AVX101 contains only one of the many substances that HIV needs to make more copies of itself; therefore, the vaccine cannot cause HIV or AIDS.
Details: This study will evaluate the safety and immunogenicity of an alphavirus replicon HIV subtype C gag vaccine. This vaccine utilizes a propagation-defective replicon vector system derived from an attenuated strain of Venezuelan Equine Encephalitis (VEE) virus. The vaccine replicon expresses the gag gene from a South African subtype C isolate of HIV-1. This study will evaluate the AVX101 vaccine in healthy, HIV uninfected volunteers in both the United States and South Africa. Participants will be randomized to receive either vaccine or placebo at study entry and again at Months 1 and 3. The study will involve four groups of participants in both the US and South Africa, with successive groups receiving increasing doses of the vaccine. Twelve US participants (US Group 1) will be randomized to receive either vaccine or placebo. After a review of initial safety data from this group, 12 South African participants (SA Group 1) will be randomized to receive the same vaccine dose as US Group 1 or placebo, while 12 US participants (US Group 2) will be randomized to receive the next higher vaccine dose or placebo. Review of safety data from SA Group 1 and US Group 2 will inform the decision to begin enrollment into SA Group 2 and US Group 3. This process of review and dose escalation will continue until the study has enrolled participants into all four SA and US Groups or until dose escalation is stopped due to safety concerns. Participants will have nine study visits over 12 months. Study visits will include clinical evaluation, urine and blood tests, and HIV tests. After each injection, participants will be asked to record their temperature and any symptoms each day for 7 days and report them to the clinic staff.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/60 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - HIV negative - Willing to receive HIV test results - Good general health - Acceptable methods of contraception for females of reproductive potential - Hepatitis B surface antigen negative - Anti-hepatitis C virus antibody (anti-HCV) negative or negative HCV PCR if anti-HCV is positive - Access to participating site and available for follow-up during the 12 month study Exclusion Criteria - HIV vaccines or placebos in prior HIV vaccine trial - Measurable anti-VEE antibody - High risk for HIV infection according to HVTN Risk Criteria - Immunosuppressive medications within 168 days prior to first study vaccine administration - Blood products within 120 days prior to first study vaccine administration - Immunoglobulin within 60 days prior to first study vaccine administration - Live attenuated vaccines within 30 days prior to first study vaccine administration - Investigational research agents within 30 days prior to first study vaccine administration - Subunit or killed vaccines within 14 days prior to first study vaccine administration - Current tuberculosis prophylaxis or therapy - Active syphilis - Serious adverse reaction to vaccines. A person who had an adverse reaction to pertussis vaccine as a child is not excluded. - Autoimmune disease or immunodeficiency - Unstable asthma - Type 1 or Type 2 Diabetes Mellitus - Thyroid disease requiring treatment - Serious angioedema within the past 3 years - Uncontrolled hypertension - Bleeding disorder - Malignancy unless it has been surgically removed and, in the opinion of the investigator, is not likely to recur during the study period - Seizure disorder requiring medication within the past 3 years - Asplenia - Mental illness that would interfere with compliance with the protocol - Other conditions that, in the judgement of the investigator, would interfere with the study - Pregnant or breast-feeding
Total Enrollment: 96
Location and Contact Information:
Overall Study Official:
SalimKarim, Study Chair, University of Natal, Durban, South Africa
New York Blood Ctr- Union Square *Recruiting*
Bronx, New York, 10456
United States
Recruiting Pamela Brown-Peterside 212-388-0008
Chris Hani Baragwanath Hospital *Not yet recruiting*
Soweto, ,
South Africa
Not yet recruiting
Vanderbilt University *Recruiting*
Nashville, Tennessee, 37232
United States
Recruiting Kyle Rybczyk 615-322-5641
Columbia University *Recruiting*
New York City, New York, 10032
United States
Recruiting Steven Chang 212-305-1570
Johns Hopkins University *Recruiting*
Baltimore, Maryland, 21205-1901
United States
Recruiting Eric Zimmerman 410-955-7283
University of Rochester Medical Center *Recruiting*
Rochester, New York, 14642-0002
United States
Recruiting Catherine Bunce 585-275-5744
SAAVI Vaccine Research Unit *Not yet recruiting*
Durban, ,
South Africa
Not yet recruiting
Additional Information:
Study ID Numbers: HVTN 040;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00063778
Other Hiv Infections Studies:
1. A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients
2. Neurodevelopmental and Neurological Study of Infants and Children With HIV-1 Infection and AIDS in Clinical Trials
3. Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults
4. A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection
5. A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)
Related Studies:
Other HIV Infections Clinical Trials
Other Clinical Trials
Other Soweto Clinical Trials
Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa
|
|
|
|
|
|
|
|
